Acorda Therapeutics, Inc. (NASDAQ: ACOR) is getting some of its lost mojo back. The company’s fampridine-SR for multiple sclerosis was given a favorable FDA panel review yesterday in a 12-1 vote in support of a future marketing approval for the drug. The stock was halted yesterday and FDA comments last week battered the stock. This morning we have a 54% gain to $25.90 after Tuesday’s $16.74 close. As of 8:46 AM EST we have seen a whopping 1.7 million shares trade hands, making this already an exponential volume alert versus 800,000 on average and the market is not even officially yet open.
JON C. OGG
OCTOBER 15, 2009